PartnershipAug 4, 2026, 07:31 AM
Dyadic Expands Non-Animal Dairy Pipeline with New European Partnership
AI Summary
Dyadic International, Inc. announced a new development and commercial license agreement with a European biotechnology company to expand its commercial non-animal dairy pipeline. This agreement focuses on additional precision-fermented dairy proteins, leveraging Dyadic's Dapibus™ platform. The company is eligible to receive development and commercial payments, licensing revenues, and other economic participation, reinforcing its strategy for recurring revenue opportunities and commercial growth.
Key Highlights
- Signed new development and commercial license agreement with a European biotechnology company.
- Agreement focuses on additional precision-fermented dairy proteins.
- Expands Dyadic's commercial non-animal dairy pipeline.
- Dyadic is eligible for development, commercial payments, licensing revenues, and economic participation.
- Leverages Dyadic's proprietary Dapibus™ precision fermentation platform.
- Builds on existing partnerships with Inzymes ApS and BRIG BIO for dairy proteins.
Price Impact
More from DYAI